Free community meeting provides annual summary of international breast cancer symposium
SAN ANTONIO (January 18, 2010) – South Texas researchers will summarize the latest information on breast cancer, including a discussion of circulating tumor cells in the bloodstream, in a free half-day community review of the San Antonio Breast Cancer Symposium this Saturday.
New therapies, obesity and breast cancer, and advances in mammography and imaging will be among the other topics in the Saturday, Jan. 22 review sponsored by the Alamo Breast Cancer Foundation.
“This is an opportunity for any person with an interest in breast health to hear the most advanced information available, and to ask the questions that are most important to them,” said Peter Ravdin, M.D., Ph.D., director of the Comprehensive Breast Health Center at the UT Health Science Center San Antonio’s Cancer Therapy & Research Center.
Among the speakers will be Dr. Ravdin, who will talk about breakthroughs in endocrine therapy and other issues; Rong Li, Ph.D., a professor of molecular medicine at the UT Health Science Center, who will discuss circulating tumor cells and cancer stem cells; and Pamela Otto, M.D., the director of the CTRC’s breast imaging center, who will speak on advances in mammography.
The review runs from 9 a.m. to 1 p.m., with registration at 8:30 a.m. at the La Quinta Inn & Conference Center, 4431 Horizon Hill, San Antonio, Texas. Continental breakfast will be served. To RSVP, contact the Alamo Breast Cancer Foundation at 210-838-5832, or email@example.com.
Co-sponsors include the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, the San Antonio Breast Cancer Symposium and Komen for the Cure, San Antonio Affiliate.
The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the elite academic cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only four in Texas. A leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) conducts one of the largest oncology Phase I clinical drug programs in the world, and participates in development of cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit www.ctrc.net.